Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer

A substantial fraction of early-stage triple-negative breast cancer (eTNBC) is characterized by high levels of stromal tumor-infiltrating lymphocytes (sTIL) and has a good prognosis even without systemic treatment, highlighting the importance of an endogenous anticancer immune response. Still, a con...

Descripción completa

Detalles Bibliográficos
Autores principales: Nederlof, Iris, Voorwerk, Leonie, Kok, Marleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320476/
https://www.ncbi.nlm.nih.gov/pubmed/36622327
http://dx.doi.org/10.1158/1078-0432.CCR-22-0701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320476/
https://www.ncbi.nlm.nih.gov/pubmed/36622327
http://dx.doi.org/10.1158/1078-0432.CCR-22-0701

Ejemplares similares